Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Free Report) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.68 and traded as high as $0.80. Brainstorm Cell Therapeutics shares last traded at $0.7917, with a volume of 4,904 shares changing hands.
Brainstorm Cell Therapeutics Price Performance
The company’s 50 day moving average price is $0.79 and its 200 day moving average price is $0.68. The firm has a market capitalization of $8.74 million, a P/E ratio of -0.24 and a beta of 0.22.
About Brainstorm Cell Therapeutics
BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) is a clinical‐stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function.
The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS).
See Also
- Five stocks we like better than Brainstorm Cell Therapeutics
- Marvell Stock Soars on NVIDIA’s Trillion-Dollar Nod
- FirstCash Turns Pawn Into a Growth Machine
- HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead?
- Aggressive Insider Buying Signals Opportunity in 3 Risky Stocks
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
